忠实航空 ALGT 深 沪
已收盘 07-02 16:00:00 美东时间
118.67
-0.490
-0.41%
华盛通- 最 高123.63
- 今 开120.01
- 成交量 61.52万股
- 最 低 115.42
- 昨 收 119.16
- 总市值 318.96万
- 52周最高 123.63
- 市盈率 静 --
- 换手率 2288.73%
- 52周最低 42.56
- 委 比 -57.52%
- 总股本 2.69万
- 历史最高 268.89
- 量 比 0.56
- 振 幅 6.89%
- 历史最低 21.16
- 每 手 1
- 风险率 16.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Goldman Sachs raises airlines' outlook, downgrades SkyWest on block hour guidance
Goldman Sachs is raising its outlook on the airline industry as strong demand for air travel has yet to be blunted by increased fares to compensate for higher fuel prices. Accordingly, the firm raised...
07-02 23:19
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
Higher Airfares Are Sticking After Spring Price Hikes, Analyst Says
Bank of America Securities (BofA) analyst Andrew G. Didora has adopted a more positive outlook on U.S. airlines ahead of second-quarter earnings, citing strong demand, stable fares, and lower fuel prices as key sector supports. BofA noted that spring fare increases have mostly persisted, and stable ...
07-02 01:48
Allegiant Travel boosts Q2 outlook after Sun Country deal
Allegiant Travel Company ( ($ALGT) ) has issued an update. Following Allegiant ...
06-30 21:16
美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级
今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元
06-29 15:49
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Evercore ISI Group Maintains Outperform on Allegiant Travel, Raises Price Target to $130
Evercore ISI Group analyst Duane Pfennigwerth maintains Allegiant Travel (NASDAQ:ALGT) with a Outperform and raises the price target from $120 to $130.
06-25 21:46
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
